On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

A newly identified mechanism lends credence to the idea that MS may be treatable by targeting EBV-infected B-cells, a study found.

Immune cells called B cells make antibodies that fight off invading bacteria, viruses and other foreign substances. During their preparation for this battle, B cells transiently revert to a more ...

New study demonstrates how high-affinity B cells 'bank' their best traits instead of rolling the dice and risking deleterious mutations, with implications for better vaccine design. A vaccine's ...